Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 4/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 3/20 | 0.31 |
| ▸ | DRD3 | P35462 | 3/20 | 0.30 |
| ▸ | TTR | P02766 | 1/20 | 0.30 |
| ▸ | ALB | P02768 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6655597 | 0.82 | NSD2 (0.38) | IDH1PGR | |
| SCHEMBL5489913 | 0.71 | — | — | |
| SCHEMBL1995598 | 0.71 | HDAC8 (0.39) | CYP2A6DRD2ARPGRTTR | |
| SCHEMBL1779094 | 0.71 | — | — | |
| SCHEMBL5157095 | 0.70 | — | — | |
| SCHEMBL11073134 | 0.69 | — | — | |
| SCHEMBL25422171 | 0.67 | — | — | |
| SCHEMBL4043065 | 0.65 | ATM (0.39) | CYP11B2 | |
| SCHEMBL20764479 | 0.64 | TDP1 (0.41) | AR | |
| SCHEMBL4075725 | 0.64 | ALDH1A1 (0.34) | ARPGRTTRALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168170-A1 | PROCESS FOR THE PREPARATION OF HETEROCYCLIC ESTER DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168170-A1 | PROCESS FOR THE PREPARATION OF HETEROCYCLIC ESTER DERIVATIVES | FLT3, FES, FLT1 | CYP2A6 634/4885CYP11B2 580/4885DRD2 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.